Groprinosine

Active substance: Inosin pranobeks
ATX Code: J05AX05
KFH: Immunostimulating drug
ICD-10 codes (readings): A60, A81.1, B00, B01, B02
CFU Code: 09.01.05.03
Manufacturer: GRODZISK PHARMACEUTICAL WORKS POLFA Co. Ltd. (Poland)

DRUGS FORM, COMPOSITION AND PACKAGING

Pills white, round, biconvex, with a risk for division on one side; with a homogeneous, smooth surface without stains and damage.

	1 table.
inosine pranobex	500 mg

Excipients: potato starch, polyvinylpyrrolidone, magnesium stearate.
25 pcs. - blisters (2) - packs of cardboard.

PHARMACHOLOGIC EFFECT

Immunostimulating drug with antiviral effect. It is a complex containing inosine and N, N-dimethylamino-2-propanol in the molar ratio 1: 3.

The effectiveness of the complex is determined by the presence of inosine, the second component increases its availability for lymphocytes. Groprinsin stimulates biochemical processes in macrophages, increases the production of interleukins. Enhances the synthesis of antibodies, enhances the proliferation of T-lymphocytes, T-helpers, natural killer cells.

Stimulates the chemotactic and phagocytic activity of monocytes, macrophages and polymorphonuclear cells. Groprinosin suppresses the replication of DNA and RNA viruses by binding to the cell's ribosome and changing its stereochemical structure.

The drug is well tolerated, because has a low toxicity. It can be prescribed to patients in old age with angina pectoris or chronic circulatory failure.

With the timely use of the drug, the incidence of viral infections decreases, the duration and severity of the disease decreases.

The use of the drug is indicated for patients with insufficient immune protection.

When Gropronosin is prescribed as an auxiliary drug for infection of the mucous membranes and skin caused by the Herpes simplex virus, faster healing of the affected surface occurs than with conventional treatment. More rarely new vesicles, swelling, erosion and relapse of the disease.

PHARMACOKINETICS

Suction
After ingestion, the drug is well absorbed from the digestive tract and is characterized by good bioavailability.

Metabolism and excretion
Rapidly metabolized. Inosine is metabolized by a cycle typical of purine nucleotides, with the formation of uric acid, a level of which in the blood serum can sometimes increase. As a result, it is possible to form crystals of uric acid in the urinary tract. No cumulation of the drug in the body.

It is excreted by the kidneys. Complete elimination of the drug and its metabolites from the body occurs during 48 h.

INDICATIONS

- immunodeficiency conditions caused by viral infections in patients with normal and weakened immune system, incl. diseases caused by viruses Herpes simplex types 1 and 2 (including genital herpes and herpes of other localization);

- subacute sclerosing panencephalitis.

DOSING MODE

The drug is taken orally after meals, at regular intervals (8 or 6 h) 3-4 times / day.

Adults Assign a dose of 3-4 g (from 6 to 8 tab.) / day, divided into 3-4 reception.
Children between the ages of 2 and 12 prescribe a dose of 50 mg / kg / day, divided into 3-4 reception.
У **adults and children** at *severe infectious diseases* the dose can be increased individually under the supervision of a doctor to 100 mg / kg / day in 4-6 receptions.
The drug is usually used for 5 days, sometimes longer, depending on the course of the disease. After 8-day break, the course of treatment can be repeated.

Tablets are taken with a small amount of water.

SIDE EFFECT

The development of adverse reactions is possible at the beginning of treatment.

From the digestive system: decreased appetite, nausea, vomiting, diarrhea.
Other: a slight increase in the concentration of uric acid in the blood and urine, allergic reactions.

CONTRAINDICATIONS

- gout;

- urolithiasis disease;

- Arrhythmia;

- Children's age up to 2 years;

- Pregnancy;

- the period of lactation (breastfeeding);

- Hypersensitivity to the components of the drug.

PREGNANCY AND LACTATION

The drug is contraindicated in pregnancy and lactation (breastfeeding), t. its safety in this category of patients is not established.

SPECIAL INSTRUCTIONS

Do not prescribe the drug to patients with hyperuricemia in connection with the possibility of increasing the content of uric acid in the serum and urine. If you need to use the drug in this category of patients should regularly monitor the content of uric acid in the body. Patients with a significant increase in the content of uric acid are encouraged to simultaneously take drugs that lower its level.

Patients with acute hepatic impairment require a reduction in the dose of the drug. the process of metabolism of inosine pranobeks occurs in the liver.

In elderly patients, dose adjustment is not required.

Impact on the ability to drive vehicles and manage mechanisms
For patients taking Groprinosin, there are no special contraindications regarding the driving of vehicles and the maintenance of moving mechanisms.

OVERDOSE

Data on the overdose of Groprinosin are not available.

DRUG INTERACTION
Immunosuppressants reduce the effectiveness of the drug.

TERMS OF RELEASE FROM PHARMACY

The drug is released by prescription.

TERMS AND CONDITIONS OF STORAGE

The drug should be stored out of the reach of children, dry, protected from light at room temperature not higher than 25 ° C. Shelf life is 3 years.